Robert F. Friel
Known title: DirectorCIK: 0001224110
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
Transaction History
| XYL | ▲ Buy | Grant | 2,481 | $290K | 5/14/2026 | View on chart |
| WST | ▲ Buy | Grant | 791 | $0 | 5/4/2026 | View on chart |
| XYL | ▲ Buy | Grant | 1,851 | $235K | 5/13/2025 | View on chart |
| WST | ▲ Buy | Grant | 1,071 | $0 | 5/6/2025 | View on chart |
| XYL | ▲ Buy | Grant | 1,647 | $0 | 5/16/2024 | View on chart |
| WST | ▲ Buy | Grant | 564 | $0 | 4/23/2024 | View on chart |
| XYL | ▲ Buy | Grant | 2,250 | $0 | 5/18/2023 | View on chart |
| WST | ▲ Buy | Grant | 616 | — | 4/25/2023 | View on chart |
| WST | ▲ Buy | Grant | 632 | — | 5/24/2022 | View on chart |
| XYL | ▲ Buy | Grant | 2,627 | $0 | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xylem sees broad analyst price target cuts
Several major banks, including Mizuho, Oppenheimer, and Citigroup, recently lowered their price targets for Xylem. While most firms maintained positive ratings, the reduction in targets reflects a more conservative outlook on the stock's near-term value. The company also announced it will participate in upcoming investor conferences to discuss its strategy.
Xylem sees broad analyst price target cuts. Several major banks, including Mizuho, Oppenheimer, and Citigroup, recently lowered their price targets for Xylem. While most firms maintained positive ratings, the reduction in targets reflects a more conservative outlook on the stock's near-term value. The company also announced it will participate in upcoming investor conferences to discuss its strategy.